

Published in final edited form as:

Nat Cell Biol. 2011 January ; 13(1): 87–94. doi:10.1038/ncb2139.

CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells

Yongkun Wei¹, Ya-Huey Chen², Long-Yuan Li^{2,3,4,9}, Jingyu Lang¹, Su-Peng Yeh⁵, Bin Shi¹, Cheng-Chieh Yang¹, Jer-Yen Yang¹, Chun-Yi Lin², Chien-Chen Lai^{6,7}, and Mien-Chie Hung^{1,2,3,4,8,9}

¹Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

²Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan

³Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan

⁴Asia University, Taichung 413, Taiwan

⁵Division of Hematology and Oncology, Department of Medicine, China Medical University and Hospital, Taichung 404, Taiwan

⁶Graduate Institute of Chinese Medical Science, China Medical University, Taichung 404, Taiwan

⁷Institute of Molecular Biology, National Chung Hsing University, Taichung 402, Taiwan

⁸Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA

Abstract

Enhancer of zeste homologue 2 (EZH2) is the catalytic subunit of Polycomb repressive complex 2 (PRC2) and catalyses the trimethylation of histone H3 on Lys 27 (H3K27), which represses gene transcription. EZH2 enhances cancer-cell invasiveness and regulates stem cell differentiation. Here, we demonstrate that EZH2 can be phosphorylated at Thr 487 through activation of cyclin-dependent kinase 1 (CDK1). The phosphorylation of EZH2 at Thr 487 disrupted EZH2 binding with the other PRC2 components SUZ12 and EED, and thereby inhibited EZH2 methyltransferase activity, resulting in inhibition of cancer-cell invasion. In human mesenchymal stem cells, activation of CDK1 promoted mesenchymal stem cell differentiation into osteoblasts through phosphorylation of EZH2 at Thr 487. These findings define a signalling link between CDK1 and

© 2010 Macmillan Publishers Limited. All rights reserved.

⁹Correspondence should be addressed to L.-Y.L. or M.-C.H. (lyl@mail.cmu.edu.tw or mhung@mdanderson.org).

Note: Supplementary Information is available on the Nature Cell Biology website

Author Contributions

M.-C.H., Y.W. and L.-Y.L. designed the project and wrote the paper. M.-C.H. and L.-Y.L. supervised the research. Y.W. performed most of the experiments in Figs 1–3. Y.-H.C. performed mesenchymal stem cell experiments in Figs 4 and 5 and experiments investigating the interaction between EZH2 and CDK1. C.-C.L. performed the mass spectrometry analysis. C.-Y.L. generated and characterized the phospho-EZH2 antibody. S.-P.Y. collected and characterized primary human mesenchymal stem cells. J. L., B.S., C.-C.Y. and J.-Y.Y. assisted with experiments. All authors participated in interpreting the results.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

EZH2 that may have an important role in diverse biological processes, including cancer-cell invasion and osteogenic differentiation of mesenchymal stem cells.

The Polycomb group (PcG) protein EZH2 is a histone lysine methyltransferase associated with transcriptional repression. EZH2 functions in the multi-protein complex PRC2, which includes SUZ12 (suppressor of zeste 12) and EED (embryonic ectoderm development)1-2. EZH2 catalyses the addition of methyl groups to histone H3 at Lys 27 (H3K27) in target gene promoters, leading to epigenetic silencing. EZH2 has an important role in controlling biological processes including X-chromosome inactivation, germline development, stem cell pluripotency and cancer metastasis3.

EZH2 is aberrantly overexpressed in aggressive solid tumours and overexpression of EZH2 has been implicated in cancer progression and metastases⁴⁻⁷. In addition, *EZH2* knockdown leads to decreased proliferation of cancer cells and a delay in the G2/M transition of the cell cycle⁸. As EZH2 has a role in the G2/M transition and CDK1 is one of the major G2/M kinases, and because both have a central function in controlling self-renewal and lineage specification of stem cells⁹, we investigated whether EZH2 is regulated by CDK1.

First, we investigated whether alteration of CDK1 activity affects H3K27 trimethylation. H3K27 trimethylation was increased in several cancer-cell lines after treatment with a CDK1 inhibitor, CGP74514A¹⁰, at a concentration (2 μ M) that is specific to CDK1 in these lines (Fig. 1a). The activity of CDK1 was inhibited by CGP74514A, as assessed by *in vitro* kinase assay of CDK1 using histone H1 as a substrate (Fig. 1a, bottom). There was no change in EZH2, SUZ12 and EED protein level. In addition, H3K27 trimethylation level increased in accordance with CGP74514A in a dose- and time-dependent manner (Supplementary Information, Fig. S1a, b). Similar results were found when cells were treated with Roscovitine, a pan-CDK inhibitor (data not shown). Consistently, knockdown of endogenous *CDK1* expression by two different shRNA (to exclude potential off-target effects of the shRNA), or by small interfering RNA (siRNA), enhanced H3K27 trimethylation (Fig. 1b and Supplementary Information, Fig. S1c). In addition, expression of a dominant-negative mutant CDK1 (DN-CDK1; ref. 11) also increased H3K27 trimethylation (Fig. 1c). As we had found that H3K27 trimethylation is increased with inhibition of CDK1 we next examined whether inhibition of CDK1 activity affects the expression of known EZH2-target genes. We tested gene expression of the *HOXA* family members using quantitative reverse transcription polymerase chain reaction (qRT-PCR). We found that expression of *HOXA* genes was suppressed by treatment with CGP74514A (Fig. 1d), indicating that inhibition of CDK1 affects the expression of EZH2-target genes.

As inactivation of CDK1 enhances trimethylation of H3K27, resulting in downregulation of EZH2-targeted gene expression, we next investigated whether CDK1, a serine/threonine kinase, might inhibit histone methyltransferase (HMTase) activity of EZH2 through phosphorylation of EZH2. We first examined whether CDK1 physically interacts with EZH2 by a co-immunoprecipitation experiment, which demonstrated an association between Myc-tagged EZH2 and haemagglutinin (HA)-tagged CDK1 (Fig. 2a). We further validated the interaction using a GST pulldown assay to demonstrate that CDK1 binds to EZH2 (Fig. 2b). Importantly, this association was also detected with endogenous CDK1 and EZH2 by reciprocal immunoprecipitation, indicating that these two molecules interact *in vivo* (Fig. 2c).

Next, we investigated whether CDK1 is able to phosphorylate EZH2. An *in vitro* kinase assay demonstrated that CDK1 catalysed the phosphorylation of EZH2, but not glutathione *S*-transferase (GST; data not shown). Mass spectrometry analysis was used to identify which residue in EZH2 is phosphorylated. We found that Thr 487 of EZH2 was phosphorylated

both *in vivo* (Supplementary Information, Fig. S2a), and *in vitro* by CDK1 (Fig. 2d). When we replaced the Thr 487 residue with alanine (EZH2^{T487A}), CDK1 was no longer able to phosphorylate the mutant EZH2, as assessed by *in vitro* CDK1 kinase assay (Fig. 2e). In cell culture, inhibition of CDK1 with CGP74514A also reduced the phosphorylation of wild-type EZH2 (Fig. 2f; lanes 2 and 3) and again, the phosphorylation level of EZH2^{T487A} mutant was virtually undetectable in an immunoblot using antibody against phosphorylated serine/threonine (Fig. 2f; lanes 4 versus 2). We also compared the phosphorylation level of wild-type EZH2 and EZH2^{T487A} by *in vivo* ³²P-labelling experiments. Phosphorylation of wild-type EZH2 occurred *in vivo*, but was inhibited by expression of *CDK1* shRNA (Fig. 2g). The phosphorylation level of EZH2^{T487A} was much lower than that of wild-type EZH2 and was not altered by expression of *CDK1* shRNA (Fig. 2g). These results suggested that Thr 487 is a major phosphorylation site of EZH2 *in vivo* and can be activated by CDK1.

To confirm that CDK1 does indeed phosphorylate EZH2 at Thr 487 *in vivo*, we generated an antibody that specifically recognizes EZH2 phosphorylated at Thr 487, but fails to detect an unphosphorylated EZH2 peptide (Supplementary Information, Fig. S2b). To confirm the specificity of the antibody, it was incubated with wild-type Myc-EZH2 or non-phosphorylatable Myc-EZH2^{T487A}, which were resolved on a SDS-PAGE gel and immunoblotted. The signal from the phospho-EZH2-Thr 487 antibody alone was lowered when incubated with phosphorylated peptide, but not unphosphorylated peptide (Supplementary Information, Fig. S2c). Using the phospho-EZH2-Thr 487 antibody, we immunoblotted lysates from HeLa cells co-transfected with plasmids encoding CDK1 and EZH2 or EZH2^{T487A}, which demonstrated that CDK1 stimulated the Thr 487 phosphorylation of wild-type EZH2, but not EZH2^{T487A} (Fig. 2h). The endogenous level of phosphorylated EZH2 at Thr 487 was also increased when CDK1 was overexpressed (Fig. 2i). Activation of CDK1 by treatment of cells with Nocodazole, which arrests cells in G2/M phase, can also induce endogenous EZH2 phosphorylation at Thr 487 (Fig. 2j). Furthermore, depletion of endogenous *CDK1* by transduction of cells with *CDK1* shRNA reduced EZH2 phosphorylation (Fig. 2k), suggesting that endogenous CDK1 is required for EZH2 phosphorylation at Thr 487. These data indicate that EZH2 is phosphorylated at Thr 487 by CDK1 both *in vitro* and *in vivo*.

Next, we investigated whether EZH2 phosphorylation mediates the ability of CDK1 to inhibit H3K27 trimethylation. Consistently, we observed that the H3K27 trimethylation level was higher in HeLa cells transfected with plasmids encoding the mutant EZH2^{T487A} than in cells transfected with plasmids encoding wild-type EZH2 (Fig. 3a; lanes 1 and 3). Additionally, inhibition of CDK1 with CGP74514A enhanced H3K27 trimethylation in cells transfected with plasmids encoding wild-type EZH2, but not in cells transfected with plasmids encoding EZH2^{T487A} (Fig. 3a; lanes 1–4 of Fig. 3a are from the same gel). Together, these results suggest that phosphorylation of EZH2 at Thr 487 by CDK1 leads to a decrease in H3K27 trimethylation.

As CDK1 suppression of H3K27 trimethylation is mediated by EZH2, we investigated whether phosphorylation of EZH2 by CDK1 alters the HMTase activity of EZH2. An *in vitro* HMTase activity assay with oligonucleosome as the substrate showed that the EZH2^{T487A} mutant exhibited higher HMTase activity than that of wild-type EZH2 (Fig. 3b bottom, lanes 4–6 versus lanes 1–3; Fig. 3c, lane 3 versus 1). Activation of CDK1 by co-transfection of plasmids expressing cyclin B and CDK1 inhibited HMTase activity of wild-type EZH2 (Fig. 3c; lane 2 versus 1), but not EZH2^{T487A} (Fig. 3c; lane 4 versus 3). In addition, cells stably expressing EZH2^{T487A} also exhibited higher H3K27 trimethylation than that of wild-type EZH2 (Fig. 3d). Together, these results suggest that phosphorylation of EZH2 at Thr 487 by CDK1 inhibits HMTase activity of EZH2.

EZH2 forms a complex with SUZ12 and EED (PRC2) *in vivo*^{1,2} and a stable complex is required for its HMTase activity. As CDK1-mediated EZH2 phosphorylation did not change the protein level of EZH2, but inhibited its HMTase activity, we next investigated whether phosphorylation might interrupt the interaction of EZH2 with SUZ12 and EED. We examined the interaction of EZH2 with SUZ12 and EED through purification of Myc-His-tagged EZH2 complex from cell lines stably expressing wild-type EZH2 and EZH2^{T487A}. There was stronger binding between SUZ12, EED and EZH2^{T487A} when compared with wild-type EZH2 (Fig. 3b; lanes 4–6 versus lanes 1–3 and Supplementary Information, Fig. S3a and Fig. 3c; lanes 3 versus 1). Activation of CDK1 led to the inhibition of wild-type EZH2 binding to SUZ12 and EED (Fig. 3c; lane 2 versus 1), but did not affect the binding of EZH2^{T487A} (Fig. 3c; lane 4 versus 3). These data support the hypothesis that phosphorylation of EZH2 by CDK1 inhibits its HMTase activity through disruption of the binding between EZH2 and SUZ12 and EED.

To examine whether EZH2 phosphorylation mediated by CDK1 affects its transcriptional repressor function, we analysed expression levels of EZH2-target *HOXA* genes using qRT-PCR. We found that a number of genes in *HOXA* clusters are repressed by expression of EZH2^{T487A} (Fig. 3e). Consistent with these results, we found that there was high EZH2 and H3K27 trimethylation on the *HOXA7* and *HOXA9* promoters, as detected by a quantitative chromatin immunoprecipitation (qChIP) assay (Fig. 3f). These results suggest that phosphorylation of EZH2 at Thr 487 by CDK1 promotes dissociation of PRC2 and results in inhibition of its HMTase activity, which in turn derepresses genes silenced by EZH2.

As CDK1 functions as a cell-cycle kinase during G2/M phase, and also phosphorylates EZH2, we next investigated whether CDK1-mediated phosphorylation of EZH2 was regulated during the cell cycle (Fig. 3g, h). In cells with ectopically and endogenously expressed EZH2 phosphorylation of EZH2 at Thr 487 was low in G0/G1 and S phase, but much higher in G2/M phase. This is consistent with the expression level of cyclin B1, which is known to activate CDK1 activity in G2/M phase. We found phosphorylation of EZH2 at Thr 487 occurred during the cell cycle in cells stably expressing wild-type EZH2, but not in cells expressing EZH2^{T487A} (Supplementary Information Fig. S3b). In addition, the expression of several *HOXA* genes was regulated during the cell cycle, with much higher expression level in G2/M phase than in S phase, which correlated with the highest level of EZH2 phosphorylation and the lowest level of H3K27 trimethylation in G2/M phase (Fig. 3i and Supplementary Information Fig. S3b). These results suggest that CDK1 inhibits EZH2 activity and derepresses its target gene expression during cell cycle.

As EZH2 is known to enhance cell proliferation, migration and invasion^{4,5,6}, and phosphorylation of EZH2 by CDK1 at Thr 487 inhibits EZH2 HMTase activity, we further investigated the effect of the T487A mutation on EZH2-mediated biological functions. Using stable transfectants expressing wild-type EZH2 and EZH2^{T487A}, we did not observe significant differences in cell proliferation (data not shown). However, expression of EZH2^{T487A} significantly enhanced cancer cell migration and invasion (Fig. 3j, k). These results suggest that phosphorylation of EZH2 at Thr 487 by CDK1 inhibits cancer cell migration and invasion.

EZH2 has an important role in regulating stem cell pluripotency and differentiation^{12–14}. Human bone-marrow-derived mesenchymal stem cells (hMSCs) are multipotent cells¹⁵. They differentiate into chondrogenic, adipogenic or osteogenic lineages when cultured under defined *in vitro* conditions^{16–18}. hMSCs differentiate into the osteogenic lineage when cultured in osteoblast differentiation medium¹⁹. However, the mechanisms governing hMSC differentiation are not well understood. Therefore, we investigated whether CDK1 regulation of EZH2 might have a role in hMSC differentiation. Treatment of hMSCs with

osteoblast differentiation medium, but not adipocyte differentiation medium, resulted in sustained CDK1 activation (Fig. 4a). The activation of CDK1 was accompanied by an increase of EZH2 phosphorylation at Thr 487 and a decrease of H3K27 trimethylation (Fig. 4a). To determine whether the CDK1–EZH2 pathway is required for osteogenic differentiation, we used *CDK1* shRNAs to knockdown endogenous *CDK1* and measured the effects on hMSC osteogenic differentiation. Continuous incubation of hMSC with osteoblast differentiation medium for 7 days resulted in positive Alizarin Red S staining (a standard marker for osteogenic differentiation; Fig. 4b, B), as well as increased expression of osteogenic marker genes, *Runx2* and osteopontin (Fig. 4c, lanes 1 and 2), whereas knockdown of *CDK1* by three different shRNAs blocked osteogenic differentiation (Fig. 4b, D–F). The knockdown of *CDK1* by shRNA led to decreased EZH2 phosphorylation, increased H3K27 trimethylation and repression of the osteogenic markers, *Runx2* and osteopontin (Fig. 4c, lanes 3 and 4). Similar results were seen in multiple primary cultured hMSCs (Supplementary Information, Fig. S4a, b and data not shown). Together, the results suggest that the phosphorylation of EZH2 by CDK1 is critical for the osteogenic differentiation of hMSC.

Next, we investigated whether activation of CDK1 by osteogenic differentiation also led to disruption of the PRC2 complex. Indeed, the interaction of EZH2 with SUZ12 and EED was decreased when hMSCs were induced to osteodifferentiation (Fig. 4d). These results support the hypothesis that activation of CDK1 promotes osteogenic differentiation through disruption of the PRC2 complex.

Several genes have been shown to be putative targets of EZH2, such as *Runx2* and *TCF7*, which are known to be important for osteogenesis¹². To further investigate whether activation of CDK1 promotes osteogenic differentiation through disruption of the PRC2 complex, we quantified the expression of EZH2-target genes during osteogenesis by qRT–PCR. The expression of *Runx2* and *TCF7* mRNAs significantly increased during osteogenesis (Fig. 5a). Knockdown of *CDK1* by shRNA significantly inhibited the effect of osteoblast differentiation medium on the increased expression of *Runx2* and *TCF7* (Fig. 5a). Consistently, a qChIP assay indicated that osteogenic differentiation resulted in decreased binding of EZH2, SUZ12 and H3K27 trimethylation at the promoter of *Runx2* (Fig. 5b). These changes were reversed with knockdown of *CDK1* by shRNA (Fig. 5b). These results suggest that CDK1 regulates osteogenesis through suppression of methyltransferase activity of EZH2 and promotes derepression of target genes of EZH2 such as osteogenesis-related genes *Runx2* and *TCF7*.

To further expand our findings, we carried out genome-wide screening to identify EZH2-target genes in hMSCs before and after osteogenic differentiation. We performed ChIP using EZH2 antibody to immunoprecipitate EZH2 and its associated DNA, followed by hybridization with promoter microarrays (ChIP-on-chip). A large number of genes (> 4,000) bind to EZH2, but after osteogenic differentiation less than 30 genes bound (Supplementary Information, Tables S1 and S2), suggesting that EZH2 is disassociated from promoters of its target genes after osteogenic differentiation.

To validate the enrichment profiles of EZH2-target genes, we randomly selected nine EZH2-targeted genes that were bound by EZH2 in hMSC, but lost binding to EZH2 after osteodifferentiation, and quantified for EZH2 and H3K27me3 enrichments in an independent experiment (Supplementary Information, Table S3). In eight of the nine genes the qChIP experiments confirmed the ChIP-on-chip results, with very similar decreased binding of EZH2 (Fig. 5c) and H3K27me3 (Fig. 5d) at these gene promoters after osteogenic differentiation. Consistently, the mRNA expression of these eight genes increased significantly during osteogenesis (Fig. 5e). The data from the three genes that

were scored positive, *PGC*, *RARRES3* and *FBP2*, are shown in Figure 5c–e. Similar results were observed for the other five genes (Supplementary Information, Table S3, Fig. S5a, b, c).

In this study, we demonstrated a novel signal pathway in which the protein kinase CDK1 regulates the histone methyltransferase EZH2. We have found that CDK1 phosphorylates EZH2 at Thr 487 thereby disrupting EZH2 binding with SUZ12 and EED, and leading to suppression of H3K27 trimethylation and consequent derepression of target gene expression. This CDK1–EZH2 signalling pathway is important both in cell migration and invasion in cancer cells, and in the regulation of osteogenic differentiation of hMSCs through the modulation of EZH2-targeted osteogenic gene expression.

It is worthwhile to mention that while this manuscript was under revision, an interesting report was published that shows phosphorylation of EZH2 at Thr 350 by CDK1 and CDK2 is important for recruitment of EZH2 and maintenance of H3K27me3 levels at EZH2-target loci²⁰. Blockage of Thr 350 phosphorylation not only diminishes the global effect of EZH2 on gene silencing, but also mitigates EZH2-mediated cell proliferation and migration²⁰. The impact of EZH2 Thr 350 phosphorylation on H3K27me3 levels in target-gene promoters is not because of changes in stability, formation or intrinsic HMTase activity of PRC2 (ref. 20). In our current study, we have identified a different phosphorylation site of EZH2 by CDK1, Thr 487, which after phosphorylation not only inhibits binding of EZH2 to its targets on the promoter, but also inhibits HMTase activity of EZH2 through disruption of the PRC2 complex. We have further demonstrated that phosphorylation of EZH2 at Thr 487 by CDK1 stimulates mesenchymal stem cell osteogenic differentiation through derepression of putative EZH2-target genes. It is not clear whether a relationship exists between these two phosphorylation sites of EZH2. A systematic study may be required to further investigate the relationship between these two sites.

METHODS

Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturecellbiology/>

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


Acknowledgments

We thank S. A. Miller and J. Hsu for editorial assistance. We thank A. M. Labaff for characterization of EED antibody. This work was supported by grants from National Institutes of Health (grant R01 CA109311), Kadoorie Charitable Foundations, National Breast Cancer Foundation Inc. and the M. D. Anderson Cancer Center/China Medical University and Hospital Sister Foundation Funds (to M.-C.H.), NSC 96-3111-B-039 and NSC 97-3111-B-039 (to M.-C.H., L.-Y.L. and S.-P.Y.), NHRI-EX98-9603BC, DOH97-TD-I-111-TM003, DOH98-TD-I-111-TM002 (to L.-Y.L.), DOH97-TD-G-111-041 (to M.-C.H.), DOH99-TD-C-111-005, NSC99-2632-B-039-001-MY3 (to L.-Y.L. and M.-C.H.). In memory of Mrs Serena Lin-Guo for her courageous battle against breast cancer.

References

1. Cao R, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. *Science*. 2002; 298:1039–1043. [PubMed: 12351676]
2. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. *Genes Dev*. 2002; 16:2893–2905. [PubMed: 12435631]

3. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. *Curr. Opin. Genet. Dev.* 2004; 14:155–164. [PubMed: 15196462]
4. Varambally S, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature.* 2002; 419:624–629. [PubMed: 12374981]
5. Kleer CG, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proc. Natl Acad. Sci. USA.* 2003; 100:11606–11611. [PubMed: 14500907]
6. Bracken AP, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. *EMBO J.* 2003; 22:5323–5335. [PubMed: 14532106]
7. Bachmann IM, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. *J. Clin. Oncol.* 2006; 24:268–273. [PubMed: 16330673]
8. Gonzalez ME, et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. *Oncogene.* 2009; 28:843–853. [PubMed: 19079346]
9. Van Hoof D, et al. Unraveling the human embryonic stem cell phosphoproteome. *Cell Stem Cell.* 2009; 5:214–226. [PubMed: 19664995]
10. Imbach P, et al. 2, 6, 9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. *Bioorg. Med. Chem. Lett.* 1999; 9:91–96. [PubMed: 9990463]
11. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. *Science.* 1993; 262:2050–2054. [PubMed: 8266103]
12. Bracken AP, et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. *Genes Dev.* 2006; 20:1123–1136. [PubMed: 16618801]
13. Boyer LA, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. *Nature.* 2006; 441:349–353. [PubMed: 16625203]
14. Lee TI, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. *Cell.* 2006; 125:301–313. [PubMed: 16630818]
15. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. *Int. J. Biochem. Cell Biol.* 2004; 36:568–584. [PubMed: 15010324]
16. Bruder SP, et al. Mesenchymal stem cells in bone development, bone repair and skeletal regeneration therapy. *J. Cell Biochem.* 1994; 56:283–294. [PubMed: 7876320]
17. Mackay AM, et al. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. *Tissue Eng.* 1998; 4:415–428. [PubMed: 9916173]
18. Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. *Science.* 1999; 284:143–147. [PubMed: 10102814]
19. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells *in vitro*. *J. Cell. Biochem.* 1997; 64:295–312. [PubMed: 9027589]
20. Chen S, et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. *Nat. Cell Biol.* 2010; 12:1108–1114. [PubMed: 20935635]

**Figure 1.**

CDK1 negatively regulates H3K27 trimethylation. **(a)** Top: 435, SKBr3, 468 and MCF7 cells were treated with CGP74514A as indicated, and the lysates were analysed by immunoblot using antibodies against the specified proteins. Bottom: *in vitro* kinase assay. CDK1, immunoprecipitated from the cell lines treated with CGP74514A as indicated at the top, was incubated with H1 and [γ -³²P]ATP. Reaction products were resolved by SDS-PAGE and visualized by autoradiography (equal loading of H1 was assessed by Coomassie-stained gel shown at the bottom). **(b)** Lysates from MCF7 cells infected with lentiviruses expressing control or two different *CDK1* shRNA were immunoblotted with antibodies against the indicated proteins. Relative intensities of the H3K27me3 bands are shown, normalized to the H3K27me3 band from parental MCF7 cells. Bottom: *in vitro* kinase assay, performed as in **a**, with CDK1 immunoprecipitated from cells treated as indicated at the top. **(c)** Lysates of 293T cells transfected with plasmids encoding cyclin B, and CDK1 or dominant-negative mutant CDK1 (DN-CDK1) were immunoblotted with antibodies against the indicated proteins. Relative intensities of the H3K27me3 bands are shown, normalized to the H3K27me3 band from 293T cells transfected with plasmid encoding CDK1. p-CDK1-T161; CDK1 phosphorylated at Thr 161. Bottom: *in vitro* kinase assay, performed as in **a**, with CDK1 immunoprecipitated from cells transfected as indicated at the top. **(d)** Left top: immunoblot of lysate from HEK293 cells treated with DMSO or CGP using antibodies

against the indicated proteins. Left bottom: *in vitro* kinase assay, performed as in **a**, with CDK1 immunoprecipitated from cells treated as indicated at the top. Right: analysis of mRNA levels of *HOXA* families by qRT-PCR after treatment of HEK293 cells with DMSO or CGP74514A. Data are means \pm s.e.m. ($n = 3$). Uncropped images of blots are shown in Supplementary Information, Fig. S6.




Figure 2.

CDK1 interacts with, and phosphorylates, EZH2 at Thr 487. **(a)** Lysates from 293T cells, transfected with plasmids encoding Myc–EZH2 and HA–CDK1 as indicated, were immunoprecipitated (IP) using anti-Myc and analysed by immunoblot using anti-Myc or anti-HA. IgG; immunoglobulin G. **(b)** Pulldowns. GST and GST–EZH2 were incubated with lysate from HeLa cells. Bound CDK1 was detected by immunoblotting. **(c)** Lysate from MCF7 cells was immunoprecipitated with antibodies against EZH2 (left) or CDK1 (right), and analysed by immunoblotting. **(d)** Cyclin B, CDK1 and GST–EZH2 were subjected to an *in vitro* kinase assay and analysed by mass spectrometry. The spectrum of the charged ion (m/z 724.7217) shows that Thr 487 is phosphorylated (lower case p) in the indicated peptide (top right). b ions, fragmentation ions containing the amino terminus of the peptide; y ions, fragmentation ions containing the carboxy terminus of the peptide. **(e)** *In vitro* kinase assay with CDK1, cyclin B, and wild-type GST–EZH2 (WT) or GST–EZH2^{T487A}.

Phosphorylation of EZH2 and H1 was visualized by autoradiography, and loading of GST–EZH2 and H1 was assessed by Coomassie-stained gel. **(f)** 293T cells were transfected with plasmids encoding wild-type Myc–EZH2 or Myc–EZH2^{T487A} and treated with CDK1 inhibitor CGP74514A or DMSO. Lysates were immunoprecipitated with anti-Myc and analysed by immunoblotting. **(g)** MCF7 cells stably expressing wild-type Myc–EZH2 or Myc–EZH2^{T487A} were transfected with control vector or plasmids encoding CDK1 and cyclin B, and infected with lentivirus expressing *CDK1* shRNA, as indicated. Cells were labelled with [³²P]-orthophosphate, EZH2 was immunoprecipitated from lysates with anti-Myc and analysed by autoradiography. Immunoblotting was used to confirm equal loading of EZH2 (bottom). **(h)** HeLa cells expressing Myc–EZH2 or Myc–EZH2^{T487A} were transfected with plasmid encoding CDK1 and cyclin B, or control vector. Cell lysates were immunoprecipitated with anti-Myc and immunoblotted. **(i)** Lysates of HeLa cells transfected with plasmid encoding CDK1 and cyclin B, or control vector, were immunoprecipitated with anti-EZH2, and immunoblotted. **(j)** Immunoblot of lysates from HeLa cells treated with Nocodazole as indicated. Cell lysates were immunoprecipitated with anti-EZH2. **(k)** MCF7 cells stably expressing wild-type Myc–EZH2 were infected with lentivirus expressing control or *CDK1* shRNA. Cell lysates were immunoprecipitated with anti-Myc and immunoblotted. Uncropped images of blots are shown in Supplementary Information, Fig. S6.




Figure 3.

CDK1-mediated phosphorylation of EZH2 promotes disassociation of EZH2 from SUZ12 and EED and suppresses EZH2 HMTase activity. **(a)** HeLa cells were transfected with plasmids encoding wild-type EZH2 or EZH2^{T487A} and treated with CGP74514A as indicated. Top: immunoblot. Relative intensity of the H3K27me3 bands is indicated. Bottom: Autoradiograph and immunoblot of *in vitro* kinase assay using H1 as substrate. **(b)** *In vitro* histone methyltransferase assay. PRC2 complexes were purified from MCF7 cell lines stably expressing wild-type Myc-His-EZH2 or Myc-His-EZH2^{T487A} and 0.5, 1 and 2 μ g were used in the assay. Top: immunoblots of purified proteins. Bottom: proteins were incubated with oligonucleosome and ³H-labelled *S*-adenosylmethionine. Methylation was assessed by autoradiography and oligonucleosome loading by Coomassie-stained gel. Relative intensities of bands are indicated at the top of each panel. **(c)** MCF7 cell lines as in **b** were transfected with control vector or plasmids encoding HA-CDK1. Left: immunoblots of experiment performed as in **b**. Right: immunoblot of lysates from MCF7 cells used in protein purification. **(d)** Immunoblot of lysates from stable MCF7 transfectants, established by transfection of cells with control vector or plasmids encoding Myc-EZH2 or Myc-EZH2^{T487A}. **(e)** qRT-PCR of *HOXA* genes in MCF7 cell lines described in **d**. Data are means \pm s.d. from three individual experiments. **(f)** Quantitative chromatin immunoprecipitation analysis on *HOXA7* and *HOXA9* promoters in MCF7 cell lines as described in **d**. Data are means \pm s.d. from three individual experiments. **(g)** Immunoblot of MCF7 cell lines stably expressing wild-type EZH2, treated by serum starvation (to collect cells at G0/G1 phase) or by double thymidine blockage and release (to collect cells at S and G2/M phases). **(h)** Immunoblot of HeLa cells treated as in **g**. **(i)** qRT-PCR of *HOXA* gene expression in MCF7 stable cell lines treated as in **g**. Data are means \pm s.d. from three individual experiments. **(j)** Images and quantification of cell migration of MCF7 stable cell lines. Data are means \pm s.e.m. from three individual experiments. **(k)** Images and quantification of cell invasion of MCF7 stable cell lines. Data are means \pm s.e.m. from three individual experiments. Uncropped images of blots are shown in Supplementary Information, Fig. S6.





Figure 4. Phosphorylation of EZH2 by CDK1 promotes osteogenic differentiation of human mesenchymal stem cells. **(a)** Osteoblast differentiation medium induces activation of CDK1 in hMSCs. Immunoblot of lysates from undifferentiated cells or cells differentiated into osteoblasts or adipocytes. **(b)** hMSCs were left untreated or were treated with osteoblast differentiation medium (OM) and shRNA as indicated. Alizarin Red S staining was performed at day 7. Differentiated stem cells positive for Alizarin Red S are stained red. **(c)** Effect of *CDK1* knockdown on the expression of osteogenic-specific genes in hMSCs. Cells were cultured in control medium or osteoblast differentiation medium, and infected with lentiviruses expressing control or *CDK1* shRNA as indicated. Cell lysates were subjected to immunoblot analysis. **(d)** Disruption of PRC2 complex after osteogenic differentiation. Lysates from cells undifferentiated or differentiated into osteoblasts were immunoprecipitated with EZH2 antibody and subjected to immunoblot analysis as indicated.

**Figure 5.**

CDK1 regulates EZH2-target gene expression in human mesenchymal stem cells. **(a)** Effect of *CDK1* knockdown on the expression of EZH2-target genes in hMSCs. Cells were cultured in control medium or osteoblast differentiation medium with or without *CDK1* shRNA. mRNA levels of *Runx2* (left) and *TCF7* (right) were measured by qRT-PCR, and are calculated relative to *GAPDH* expression. Data are means \pm s.e.m. ($n = 3$). **(b)** Effect of *CDK1* knockdown on the binding of EZH2 to *Runx2* gene promoter in hMSCs. Cells were cultured in control medium or osteoblast differentiation medium with or without *CDK1* shRNA infection. Quantitative chromatin immunoprecipitation was performed using antibodies against the indicated proteins on the *Runx2* promoter. Levels of CDK1 are shown by immunoblot (top). **(c, d)** Four genes shown to have differential EZH2 binding after osteogenic differentiation from a genome-wide ChIP-on-chip assay were randomly selected for ChIP assay using antibodies against EZH2 (**c**) and H3K27me3 (**d**). hMSCs were cultured in control medium or osteoblast differentiation medium. **(e)** The expression of the four genes analysed in **c** and **d** was assessed by qRT-PCR from hMSCs cultured in control medium or osteoblast differentiation medium.